News
IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam ...
MELBOURNE, Australia and INDIANAPOLIS, April 15, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback